Temozolomide

Generic Name
Temozolomide
Brand Names
Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
Drug Type
Small Molecule
Chemical Formula
C6H6N6O2
CAS Number
85622-93-1
Unique Ingredient Identifier
YF1K15M17Y
Background

Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...

Indication

Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.

Associated Conditions
Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
Associated Therapies
-
Clinical Trials
Related News

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

First Posted Date
2020-05-21
Last Posted Date
2024-03-26
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
2
Registration Number
NCT04397679
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

First Posted Date
2020-05-20
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
76
Registration Number
NCT04394858
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

🇺🇸

Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 158 locations

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

First Posted Date
2020-05-14
Last Posted Date
2020-06-09
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
10
Registration Number
NCT04388033
Locations
🇨🇳

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

First Posted Date
2020-05-12
Last Posted Date
2022-12-28
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
12
Registration Number
NCT04385173
Locations
🇨🇳

the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

First Posted Date
2020-05-12
Last Posted Date
2024-10-22
Lead Sponsor
Children's Oncology Group
Target Recruit Count
41
Registration Number
NCT04385277
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States

and more 74 locations

NG101m Adjuvant Therapy in Glioblastoma Patients

First Posted Date
2020-05-04
Last Posted Date
2023-04-18
Lead Sponsor
NeuGATE Theranostics
Target Recruit Count
52
Registration Number
NCT04373785
Locations
🇺🇸

Yvonne Kew MD, PLLC, Houston, Texas, United States

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

First Posted Date
2020-04-07
Last Posted Date
2024-11-26
Lead Sponsor
Valent Technologies, LLC
Target Recruit Count
20
Registration Number
NCT04337177
Locations
🇺🇸

Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, Indiana, United States

🇺🇸

Sarah Cannon Research Institute, Pediatric Hematology & Oncology, Nashville, Tennessee, United States

🇺🇸

Duke University Children's Hospital and Health Center, Durham, North Carolina, United States

and more 5 locations

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

First Posted Date
2020-03-27
Last Posted Date
2024-07-26
Lead Sponsor
Celgene
Target Recruit Count
184
Registration Number
NCT04324840
Locations
🇳🇱

Local Institution - 400, Rotterdam, Netherlands

🇳🇴

Local Institution - 600, Oslo, Norway

🇳🇱

Local Institution - 408, Leiden, Zuid-Holland, Netherlands

and more 26 locations

Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery

First Posted Date
2020-03-20
Last Posted Date
2020-03-20
Lead Sponsor
West China Hospital
Target Recruit Count
250
Registration Number
NCT04316039
Locations
🇨🇳

Xingchen Peng, Chengdu, Sichuan, China

Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma

Phase 2
Active, not recruiting
Conditions
Glioblastoma
Interventions
Drug: UCPVax
Drug: Temozolomide
First Posted Date
2020-02-21
Last Posted Date
2023-11-08
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
56
Registration Number
NCT04280848
Locations
🇫🇷

Hôpital Saint-Louis, Paris, France

🇫🇷

CHU Bordeaux, Bordeaux, France

🇫🇷

CHU Besançon, Besançon, France

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy